Teva Pharmaceuticals (NYSE:TEVA) is not only one of the biggest generic drug manufacturers in the world but it also sells Copaxone, the branded blockbuster multiple sclerosis treatment. Despite this unique business model, the company has struggled to gain investor confidence over the last few years. It's facing a number of headwinds; the clock on Copaxone's market exclusivity is ticking fast; and new competitors in the multiple sclerosis space, such as Biogen's (NASDAQ:BIIB) recently launched drug Tecfidera, are another threat to this drug's sales.
Today, Teva's future is even more uncertain after its CEO announced his resignation. In the following video from The Motley Fool's health-care show, Market Checkup, analyst Max Macaluso discusses the details behind this move and what lies ahead for the company.
Alison Southwick, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.
The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
Plans to "trim the fat" have Wall Street and investors excited.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.